



TC 1700

Goiga
5/23/02
PATENT APPLICATION

PATENT APPLICATION
Our Docket No. 960670.CNC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re App : Donald L. N. Cardy et al : May 6, 2003

S.N. : 08/737,457 : Art Unit 1644

Filed: March 12, 1997: Exam. G.R. Ewoldt

For : IMPROVEMENTS IN OR RELATING TO Paper No. 40

PEPTIDE DELIVERY

## SUPPLEMENTAL RESPONSE

RECEIVED

MAY 1 3 2003

U.S. PATENT AND TRADEMARK OFFICE Box Sequence, P.O. Box 2327 Arlington, VA 22202

TECH CENTER 1600/2900

Dear Sir:

This letter is submitted in response to a communication from the Examiner in charge of the application mailed April 29, 2003 and is supplemental to a response dated February 5, 2003.

To comply with the requirements of the Notice sent by the Examiner, applicants herewith supply a substitute computer readable form (CRF) copy of the requested "Sequence Listing". In addition, a substitute paper copy of the Sequence Listing is supplied as contained on page 1 of "Appendix A".

A copy of the Notice is also attached.

The information recorded in computer readable form is identical to the written Sequence Listing and they include no new matter.

It is believed that the application now complies with the requirements of 37 CFR 1.821-1.825 and, accordingly, they have requested that substantive examination of the claims proceed.

Respectfully submitted,

NIKOLAI & MERSEREAU, P.A.

C. G. Mersereau

Coffeeneau

C. G. Mersereau
Registration No. 26,205
Attorneys for Applicant(s)
820 International Centre
900 Second Avenue South
Minneapolis, MN 55402
(612) 339-7461

Appropriation No.: 08/737,457

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application do	es not
comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.8	825 for the
following reason(s):	

	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.8 attention is directed to the final rulemaking notice published at 55 FR 18230 (May OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).	1, 1990), and 1114 le final rulemaking				
	2. This application does not contain, as a separate part of the disclosure on paper co- Listing" as required by 37 C.F.R. 1.821(c).	py, a "Sequence				
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).					
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."					
	5. The computer readable form that has been filed with this application has been four and/or unreadable as indicated on the attached CRF Diskette Problem Report. A scomputer readable form must be submitted as required by 37 C.F.R. 1.825(d).					
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable "Sequence Listing" as required by 37 C.F.R. 1.821(e).	e from of the				
N	7. Other: Sae latter	TC 1700				
Applicant Must Provide:						
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	00 8				
X	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment into the specification.	nt directing its entry				
X	A statement that the content of the paper and computer readable copies are the same applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.825(b) or 1.825(d).					
For	For questions regarding compliance to these requirements, please contact:  RECEIVED					
For Rules interpretation, call (703) 308-4216						
For CRF Submission Help, call (703) 308-4212 Patentln Software Program Support  MAY 1 3 2003						
	Technical Assistance	TECH CENTER 1600/290				
	DI EAGE BETHEN A GOBY OF THIS MOTION MITH WALLS B					

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY





## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	Δ.	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.	
		- William			
		70 /3 20		EXAMINER	
		1700	ART UN	IT PAPER NUMBER	
		•		39	

Please find below a communication from the EXAMINER in charge of this application

The reply filed on 2/26/03 is not fully responsive to the prior Office Action for the reasons set forth below. Since the period for reply set forth in the prior Office action has expired, this application will become abandoned unless applicant corrects the deficiency and obtains an extension of time under 37 CFR 1.136(a).

The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. In no case may an applicant reply outside the SIX (6) MONTH statutory period or obtain an extension for more than FIVE (5) MONTHS beyond the date for reply set forth in an Office action. A fully responsive reply must be timely filed to avoid abandonment of this application.

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132. Specifically, Applicant must comply with the rules as set forth in MPEP 2424.02 and the Table spanning pages 2400-44 through 2400-47 of the MPEP. For example, line <140> must contain the application no., (US 08/737,457) because it is available. Line <141> must contain the current filing date, line <150> must contain all of the prior application nos., and line <151> must contain their filing dates. RECEIVED

MAY 1 3 2003

Serial Number: 08/737,457

Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner Christina Chan whose telephone number is (703) 308-3973. The fax number for the organization where this application is assigned is (703) 308-4242.

G.R. Ewoldt, Ph.D.

Primary Examiner Tech Center 1600

April 28, 2003